Long-term results of intra-arterial onyx injection for type II endoleaks following endovascular aneurysm repair
Purpose The aim of this paper is to report our experience of type II endoleak treatment after endovascular aneurysm repair with intra-arterial injection of the embolizing liquid material, Onyx liquid embolic system. Methods From 2005 to 2012, we performed a retrospective review of 600 patients, who...
Gespeichert in:
| Veröffentlicht in: | Vascular 2017-06, Vol.25 (3), p.266-271 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 271 |
|---|---|
| container_issue | 3 |
| container_start_page | 266 |
| container_title | Vascular |
| container_volume | 25 |
| creator | Ribé, L Bicknell, CD Gibbs, RG Burfitt, N Jenkins, MP Cheshire, N Hamady, M |
| description | Purpose
The aim of this paper is to report our experience of type II endoleak treatment after endovascular aneurysm repair with intra-arterial injection of the embolizing liquid material, Onyx liquid embolic system.
Methods
From 2005 to 2012, we performed a retrospective review of 600 patients, who underwent endovascular repair of an abdominal aortic aneurysm. During this period, 18 patients were treated with Onyx for type II endoleaks.
Principal findings
The source of the endoleak was the internal iliac artery in seven cases, inferior mesenteric artery in seven cases and lumbar arteries in four cases. Immediate technical success was achieved in all patients and no endoleak from the treated vessel recurred. During a mean follow-up of 19 months, no major morbidity or mortality occurred, and one-year survival was 100%.
Conclusions
Treatment of type II endoleaks with Onyx is safe and effective over a significant time period. |
| doi_str_mv | 10.1177/1708538116671467 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859722328</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1708538116671467</sage_id><sourcerecordid>1859722328</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-484e44d489d0436b2b459750a35d3b586de1158f9a6133031201738bef1f402c3</originalsourceid><addsrcrecordid>eNp1kD1PwzAURS0EolDYmZBHloCf7djOiCo-KlViAYktchKnSnHiYidA_j0uLR2QmJ51dN_R80XoAsg1gJQ3IIlKmQIQQgIX8gCdbFCSsuz1cP9WMEGnIawIYYSCOEYTKoVSNOMnyC1ct0x641vsTRhsH7CrcdP1XifaR95oi103fkW2MmXfuA7XzuN-XBs8n2PTVc4a_RYitdZ9Nt3yh33oUA5We6w7M_gxbPRr3fgzdFRrG8z5bk7Ry_3d8-wxWTw9zGe3i6RkMusTrrjhvOIqqwhnoqAFTzOZEs3SihWpEpUBSFWdaQGMEQaUgGSqMDXUnNCSTdHV1rv27n0woc_bJpTG2niPG0IOKvooZVTFKNlGS-9C8KbO175ptR9zIPmm5vxvzXHlcmcfitZU-4XfXmMg2QaCXpp85Qbfxd_-L_wG6zKFbw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1859722328</pqid></control><display><type>article</type><title>Long-term results of intra-arterial onyx injection for type II endoleaks following endovascular aneurysm repair</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Ribé, L ; Bicknell, CD ; Gibbs, RG ; Burfitt, N ; Jenkins, MP ; Cheshire, N ; Hamady, M</creator><creatorcontrib>Ribé, L ; Bicknell, CD ; Gibbs, RG ; Burfitt, N ; Jenkins, MP ; Cheshire, N ; Hamady, M</creatorcontrib><description>Purpose
The aim of this paper is to report our experience of type II endoleak treatment after endovascular aneurysm repair with intra-arterial injection of the embolizing liquid material, Onyx liquid embolic system.
Methods
From 2005 to 2012, we performed a retrospective review of 600 patients, who underwent endovascular repair of an abdominal aortic aneurysm. During this period, 18 patients were treated with Onyx for type II endoleaks.
Principal findings
The source of the endoleak was the internal iliac artery in seven cases, inferior mesenteric artery in seven cases and lumbar arteries in four cases. Immediate technical success was achieved in all patients and no endoleak from the treated vessel recurred. During a mean follow-up of 19 months, no major morbidity or mortality occurred, and one-year survival was 100%.
Conclusions
Treatment of type II endoleaks with Onyx is safe and effective over a significant time period.</description><identifier>ISSN: 1708-5381</identifier><identifier>EISSN: 1708-539X</identifier><identifier>DOI: 10.1177/1708538116671467</identifier><identifier>PMID: 27688294</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Aged ; Aged, 80 and over ; Angiography, Digital Subtraction ; Aortic Aneurysm, Abdominal - surgery ; Blood Vessel Prosthesis Implantation - adverse effects ; Computed Tomography Angiography ; Dimethyl Sulfoxide - administration & dosage ; Dimethyl Sulfoxide - adverse effects ; Drug Combinations ; Embolization, Therapeutic - adverse effects ; Embolization, Therapeutic - methods ; Endoleak - diagnostic imaging ; Endoleak - etiology ; Endoleak - therapy ; Endovascular Procedures - adverse effects ; Female ; Humans ; Iliac Artery - diagnostic imaging ; Injections, Intra-Arterial ; Lumbar Vertebrae - blood supply ; Male ; Mesenteric Artery, Inferior - diagnostic imaging ; Polyvinyls - administration & dosage ; Polyvinyls - adverse effects ; Retrospective Studies ; Tantalum - administration & dosage ; Tantalum - adverse effects ; Time Factors ; Treatment Outcome</subject><ispartof>Vascular, 2017-06, Vol.25 (3), p.266-271</ispartof><rights>The Author(s) 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-484e44d489d0436b2b459750a35d3b586de1158f9a6133031201738bef1f402c3</citedby><cites>FETCH-LOGICAL-c379t-484e44d489d0436b2b459750a35d3b586de1158f9a6133031201738bef1f402c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1708538116671467$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1708538116671467$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27688294$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ribé, L</creatorcontrib><creatorcontrib>Bicknell, CD</creatorcontrib><creatorcontrib>Gibbs, RG</creatorcontrib><creatorcontrib>Burfitt, N</creatorcontrib><creatorcontrib>Jenkins, MP</creatorcontrib><creatorcontrib>Cheshire, N</creatorcontrib><creatorcontrib>Hamady, M</creatorcontrib><title>Long-term results of intra-arterial onyx injection for type II endoleaks following endovascular aneurysm repair</title><title>Vascular</title><addtitle>Vascular</addtitle><description>Purpose
The aim of this paper is to report our experience of type II endoleak treatment after endovascular aneurysm repair with intra-arterial injection of the embolizing liquid material, Onyx liquid embolic system.
Methods
From 2005 to 2012, we performed a retrospective review of 600 patients, who underwent endovascular repair of an abdominal aortic aneurysm. During this period, 18 patients were treated with Onyx for type II endoleaks.
Principal findings
The source of the endoleak was the internal iliac artery in seven cases, inferior mesenteric artery in seven cases and lumbar arteries in four cases. Immediate technical success was achieved in all patients and no endoleak from the treated vessel recurred. During a mean follow-up of 19 months, no major morbidity or mortality occurred, and one-year survival was 100%.
Conclusions
Treatment of type II endoleaks with Onyx is safe and effective over a significant time period.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiography, Digital Subtraction</subject><subject>Aortic Aneurysm, Abdominal - surgery</subject><subject>Blood Vessel Prosthesis Implantation - adverse effects</subject><subject>Computed Tomography Angiography</subject><subject>Dimethyl Sulfoxide - administration & dosage</subject><subject>Dimethyl Sulfoxide - adverse effects</subject><subject>Drug Combinations</subject><subject>Embolization, Therapeutic - adverse effects</subject><subject>Embolization, Therapeutic - methods</subject><subject>Endoleak - diagnostic imaging</subject><subject>Endoleak - etiology</subject><subject>Endoleak - therapy</subject><subject>Endovascular Procedures - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Iliac Artery - diagnostic imaging</subject><subject>Injections, Intra-Arterial</subject><subject>Lumbar Vertebrae - blood supply</subject><subject>Male</subject><subject>Mesenteric Artery, Inferior - diagnostic imaging</subject><subject>Polyvinyls - administration & dosage</subject><subject>Polyvinyls - adverse effects</subject><subject>Retrospective Studies</subject><subject>Tantalum - administration & dosage</subject><subject>Tantalum - adverse effects</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1708-5381</issn><issn>1708-539X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kD1PwzAURS0EolDYmZBHloCf7djOiCo-KlViAYktchKnSnHiYidA_j0uLR2QmJ51dN_R80XoAsg1gJQ3IIlKmQIQQgIX8gCdbFCSsuz1cP9WMEGnIawIYYSCOEYTKoVSNOMnyC1ct0x641vsTRhsH7CrcdP1XifaR95oi103fkW2MmXfuA7XzuN-XBs8n2PTVc4a_RYitdZ9Nt3yh33oUA5We6w7M_gxbPRr3fgzdFRrG8z5bk7Ry_3d8-wxWTw9zGe3i6RkMusTrrjhvOIqqwhnoqAFTzOZEs3SihWpEpUBSFWdaQGMEQaUgGSqMDXUnNCSTdHV1rv27n0woc_bJpTG2niPG0IOKvooZVTFKNlGS-9C8KbO175ptR9zIPmm5vxvzXHlcmcfitZU-4XfXmMg2QaCXpp85Qbfxd_-L_wG6zKFbw</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Ribé, L</creator><creator>Bicknell, CD</creator><creator>Gibbs, RG</creator><creator>Burfitt, N</creator><creator>Jenkins, MP</creator><creator>Cheshire, N</creator><creator>Hamady, M</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201706</creationdate><title>Long-term results of intra-arterial onyx injection for type II endoleaks following endovascular aneurysm repair</title><author>Ribé, L ; Bicknell, CD ; Gibbs, RG ; Burfitt, N ; Jenkins, MP ; Cheshire, N ; Hamady, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-484e44d489d0436b2b459750a35d3b586de1158f9a6133031201738bef1f402c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiography, Digital Subtraction</topic><topic>Aortic Aneurysm, Abdominal - surgery</topic><topic>Blood Vessel Prosthesis Implantation - adverse effects</topic><topic>Computed Tomography Angiography</topic><topic>Dimethyl Sulfoxide - administration & dosage</topic><topic>Dimethyl Sulfoxide - adverse effects</topic><topic>Drug Combinations</topic><topic>Embolization, Therapeutic - adverse effects</topic><topic>Embolization, Therapeutic - methods</topic><topic>Endoleak - diagnostic imaging</topic><topic>Endoleak - etiology</topic><topic>Endoleak - therapy</topic><topic>Endovascular Procedures - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Iliac Artery - diagnostic imaging</topic><topic>Injections, Intra-Arterial</topic><topic>Lumbar Vertebrae - blood supply</topic><topic>Male</topic><topic>Mesenteric Artery, Inferior - diagnostic imaging</topic><topic>Polyvinyls - administration & dosage</topic><topic>Polyvinyls - adverse effects</topic><topic>Retrospective Studies</topic><topic>Tantalum - administration & dosage</topic><topic>Tantalum - adverse effects</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ribé, L</creatorcontrib><creatorcontrib>Bicknell, CD</creatorcontrib><creatorcontrib>Gibbs, RG</creatorcontrib><creatorcontrib>Burfitt, N</creatorcontrib><creatorcontrib>Jenkins, MP</creatorcontrib><creatorcontrib>Cheshire, N</creatorcontrib><creatorcontrib>Hamady, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Vascular</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ribé, L</au><au>Bicknell, CD</au><au>Gibbs, RG</au><au>Burfitt, N</au><au>Jenkins, MP</au><au>Cheshire, N</au><au>Hamady, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term results of intra-arterial onyx injection for type II endoleaks following endovascular aneurysm repair</atitle><jtitle>Vascular</jtitle><addtitle>Vascular</addtitle><date>2017-06</date><risdate>2017</risdate><volume>25</volume><issue>3</issue><spage>266</spage><epage>271</epage><pages>266-271</pages><issn>1708-5381</issn><eissn>1708-539X</eissn><abstract>Purpose
The aim of this paper is to report our experience of type II endoleak treatment after endovascular aneurysm repair with intra-arterial injection of the embolizing liquid material, Onyx liquid embolic system.
Methods
From 2005 to 2012, we performed a retrospective review of 600 patients, who underwent endovascular repair of an abdominal aortic aneurysm. During this period, 18 patients were treated with Onyx for type II endoleaks.
Principal findings
The source of the endoleak was the internal iliac artery in seven cases, inferior mesenteric artery in seven cases and lumbar arteries in four cases. Immediate technical success was achieved in all patients and no endoleak from the treated vessel recurred. During a mean follow-up of 19 months, no major morbidity or mortality occurred, and one-year survival was 100%.
Conclusions
Treatment of type II endoleaks with Onyx is safe and effective over a significant time period.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>27688294</pmid><doi>10.1177/1708538116671467</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1708-5381 |
| ispartof | Vascular, 2017-06, Vol.25 (3), p.266-271 |
| issn | 1708-5381 1708-539X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1859722328 |
| source | SAGE Complete A-Z List; MEDLINE |
| subjects | Aged Aged, 80 and over Angiography, Digital Subtraction Aortic Aneurysm, Abdominal - surgery Blood Vessel Prosthesis Implantation - adverse effects Computed Tomography Angiography Dimethyl Sulfoxide - administration & dosage Dimethyl Sulfoxide - adverse effects Drug Combinations Embolization, Therapeutic - adverse effects Embolization, Therapeutic - methods Endoleak - diagnostic imaging Endoleak - etiology Endoleak - therapy Endovascular Procedures - adverse effects Female Humans Iliac Artery - diagnostic imaging Injections, Intra-Arterial Lumbar Vertebrae - blood supply Male Mesenteric Artery, Inferior - diagnostic imaging Polyvinyls - administration & dosage Polyvinyls - adverse effects Retrospective Studies Tantalum - administration & dosage Tantalum - adverse effects Time Factors Treatment Outcome |
| title | Long-term results of intra-arterial onyx injection for type II endoleaks following endovascular aneurysm repair |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T20%3A14%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20results%20of%20intra-arterial%20onyx%20injection%20for%20type%20II%20endoleaks%20following%20endovascular%20aneurysm%20repair&rft.jtitle=Vascular&rft.au=Rib%C3%A9,%20L&rft.date=2017-06&rft.volume=25&rft.issue=3&rft.spage=266&rft.epage=271&rft.pages=266-271&rft.issn=1708-5381&rft.eissn=1708-539X&rft_id=info:doi/10.1177/1708538116671467&rft_dat=%3Cproquest_cross%3E1859722328%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1859722328&rft_id=info:pmid/27688294&rft_sage_id=10.1177_1708538116671467&rfr_iscdi=true |